Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Gossamer Bio Inc (GOSS)

Gossamer Bio Inc (GOSS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 98,346
  • Shares Outstanding, K 231,456
  • Annual Sales, $ 114,700 K
  • Annual Income, $ -56,530 K
  • EBIT $ -161 M
  • EBITDA $ -169 M
  • 60-Month Beta 1.93
  • Price/Sales 2.19
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.69
  • Most Recent Earnings $-0.21 on 11/05/25
  • Next Earnings Date 03/12/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 187.04% (-4.30%)
  • Historical Volatility 463.87%
  • IV Percentile 74%
  • IV Rank 21.42%
  • IV High 633.32% on 02/20/26
  • IV Low 65.36% on 08/20/25
  • Expected Move (DTE 19) 0.1530 (36.01%)
  • Put/Call Vol Ratio 0.90
  • Today's Volume 2,295
  • Volume Avg (30-Day) 31,272
  • Put/Call OI Ratio 0.53
  • Today's Open Interest 410,421
  • Open Int (30-Day) 422,916
  • Expected Range 0.2719 to 0.5779

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.19
  • Number of Estimates 5
  • High Estimate -0.11
  • Low Estimate -0.25
  • Prior Year -0.15
  • Growth Rate Est. (year over year) -26.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3312 +28.29%
on 02/25/26
2.7550 -84.58%
on 02/03/26
-2.2151 (-83.91%)
since 01/27/26
3-Month
0.3312 +28.29%
on 02/25/26
3.8700 -89.02%
on 12/15/25
-2.9151 (-87.28%)
since 11/26/25
52-Week
0.3312 +28.29%
on 02/25/26
3.8700 -89.02%
on 12/15/25
-0.7651 (-64.29%)
since 02/27/25

Most Recent Stories

More News
GOSS Investors Have Opportunity to Join Gossamer Bio, Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Gossamer Bio, Inc. (“Gossamer” or “the Company”)...

GOSS : 0.4249 (+5.70%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS

NEW YORK , Feb. 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS).  Such investors are advised...

GOSS : 0.4249 (+5.70%)
Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension

- Seralutinib demonstrated a placebo-adjusted improvement in Six-Minute Walk Distance (6MWD) of +13.3 meters at Week 24 (p = 0.0320), missing the prespecified alpha threshold of 0.025 - ...

GOSS : 0.4249 (+5.70%)
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension...

GOSS : 0.4249 (+5.70%)
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension...

GOSS : 0.4249 (+5.70%)
Gossamer Bio to Participate in Upcoming Investor Conferences

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension...

GOSS : 0.4249 (+5.70%)
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension...

GOSS : 0.4249 (+5.70%)
Gossamer Bio to Participate in Upcoming Investor Conferences

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension...

GOSS : 0.4249 (+5.70%)
Gossamer Bio: Q3 Earnings Snapshot

Gossamer Bio: Q3 Earnings Snapshot

GOSS : 0.4249 (+5.70%)
Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update

- Topline Results from PROSERA Phase 3 Expected in February 2026 - - First Site Activated for Registrational Phase 3 SERANATA Study in PH-ILD - ...

GOSS : 0.4249 (+5.70%)

Business Summary

Gossamer Bio Inc. is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing and commercializing therapeutics in the areas of immunology, inflammation and oncology. The company's product pipeline includes GB001, GB002, GB004, GB1275, Autoimmune program and Oncology...

See More

Key Turning Points

3rd Resistance Point 0.5049
2nd Resistance Point 0.4750
1st Resistance Point 0.4499
Last Price 0.4249
1st Support Level 0.3949
2nd Support Level 0.3650
3rd Support Level 0.3399

See More

52-Week High 3.8700
Fibonacci 61.8% 2.5182
Fibonacci 50% 2.1006
Fibonacci 38.2% 1.6830
Last Price 0.4249
52-Week Low 0.3312

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar